Table 3.
Multivariate analysis of prognostic factors for 272 patients with stage III NPC
| Variables | LRFS | DMFS | DFS | OS | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Age (≤ 43 vs. > 43, year) | – | – | – | – | 1.378 (0.884–2.148) | 0.157 | 1.946 (1.161–3.264) | 0.012 |
| Smoking (yes vs. no) | – | – | – | – | 0.728 (0.452–1.172) | 0.192 | 0.578 (0.336–0.996) | 0.048 |
| Alcohol (yes vs. no) | – | – | 0.643 (0.369–1.121) | 0.120 | 0.872 (0.506–1.502) | 0.621 | 0.839 (0.462–1.522) | 0.563 |
| N classification (N0-1 vs. N2) | 1.910 (0.930-3.920) | 0.078 | 1.683 (0.972–2.916) | 0.063 | 1.722 (1.115–2.657) | 0.014 | 1.629 (0.996–2.665) | 0.052 |
| CCT (yes vs. no) | 1.737 (0.834-3.617) | 0.140 | 1.431 (0.808–2.535) | 0.219 | 1.661 (1.064–2.594) | 0.026 | 1.876 (1.141–3.083) | 0.013 |
| EBV DNA (< 2000 vs. ≥ 2000) | 1.664 (0.713-3.883) | 0.239 | – | – | – | – | – | – |
NPC, nasopharyngeal carcinoma; HR, hazard ratio; CI, confidence interval; LRFS, locoregional-free survival; DMFS, distant metastasis-free survival; DFS, disease-free survival; OS, overall survival; CCT, concurrent chemotherapy; EBV, Epstein–Barr virus